Prosthetic joint infection after total hip or knee arthroplasty in rheumatoid arthritis patients treated with nonbiologic and biologic disease-modifying antirheumatic drugs

被引:97
|
作者
Momohara, Shigeki [1 ]
Kawakami, Kosei [1 ]
Iwamoto, Takuji [1 ]
Yano, Koichiro [1 ]
Sakuma, Yu [1 ]
Hiroshima, Ryo [1 ]
Imamura, Hitoshi [1 ]
Masuda, Ikuko [1 ]
Tokita, Asami [1 ]
Ikari, Katsunori [1 ]
机构
[1] Tokyo Womens Med Univ, Dept Orthopaed Surg, Inst Rheumatol, Shinjuku Ku, Tokyo 1620054, Japan
关键词
Disease-modifying antirheumatic drugs (DMARDs); Rheumatoid arthritis; Surgical-site infection (SSI); Total joint arthroplasty surgery; Tumor necrosis factor (TNF) blockers; FACTOR-ALPHA-BLOCKERS; EARLY POSTOPERATIVE COMPLICATIONS; ELECTIVE ORTHOPEDIC-SURGERY; ANTITUMOR NECROSIS FACTOR; RISK-FACTORS; SURGICAL-PROCEDURES; METHOTREXATE; THERAPY; REPLACEMENT; TOCILIZUMAB;
D O I
10.1007/s10165-011-0423-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of this study was to identify risk factors for acute surgical-site infection (SSI) after total joint arthroplasty in rheumatoid arthritis (RA) patients treated with nonbiologic and biologic disease-modifying antirheumatic drugs (DMARDs). We performed a retrospective study of all consecutive total hip (THA) and total knee (TKA) arthroplasties performed during a 5-year period (THA 81; TKA 339). Multivariate logistic regression analysis was performed to identify SSI risk factors. Of the patients undergoing THA or TKA, 24 cases (5.7%) developed a superficial incisional SSI requiring the use of antibiotics and three cases (0.7%) developed an organ/space SSI necessitating surgical treatment to remove the artificial joint prosthesis. Multivariate logistic regression analysis revealed that the use of biologic DMARDs [P = 0.0007, odds ratio (OR) = 5.69; 95% confidence interval (CI) 2.07-15.61] and longer RA duration (P = 0.0003, OR = 1.09; 95% CI 1.04-1.14) were the only significant risk factors for acute SSI. Furthermore, an analysis that individually evaluated major agents (n > 10) adjusted for disease duration indicated that tumor necrosis factor alpha blockers increased the risk of SSI (infliximab P = 0.001, OR = 9.80, 95% CI 2.41-39.82; etanercept P = 0.0003, OR = 9.16, 95% CI 2.77-30.25). We found that the use of infliximab or etanercept and longer disease duration were associated with an increased risk of acute SSI in RA patients. Prospective studies are thus needed to determine the safety of biologic DMARDs in the perioperative period.
引用
收藏
页码:469 / 475
页数:7
相关论文
共 50 条
  • [1] Risk of Serious Infection in Patients With Rheumatoid Arthritis Treated With Biologic Versus Nonbiologic Disease-Modifying Antirheumatic Drugs
    Ozen, Gulsen
    Pedro, Sofia
    England, Bryant R.
    Mehta, Bella
    Wolfe, Frederick
    Michaud, Kaleb
    ACR OPEN RHEUMATOLOGY, 2019, 1 (07) : 424 - 432
  • [2] Biologic Disease-Modifying Antirheumatic Drugs Do Not Increase Risk for Prosthetic Joint Infection in Setting of Total Knee Arthroplasty
    Bains, Sandeep S.
    Chen, Zhongming
    Sax, Oliver C.
    Salib, Christopher G.
    Paulson, Ambika E.
    Delanois, Ronald E.
    JOURNAL OF KNEE SURGERY, 2024, 37 (02) : 121 - 127
  • [3] POSTOPERATIVE COMPLICATIONS IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING BIOLOGIC AND NONBIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
    Pogozheva, E.
    Amirdzhanova, V.
    Makarov, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 374 - 375
  • [4] Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis
    Lacaille, Diane
    Guh, Daphne P.
    Abrahamowicz, Michal
    Anis, Aslam H.
    Esdaile, John M.
    ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2008, 59 (08): : 1074 - 1081
  • [5] Use of Nonbiologic Disease-Modifying Antirheumatic Drugs and Risk of Infection in Patients With Rheumatoid Arthritis
    Dejaco, Christian
    Duftner, Christina
    JOURNAL FUR MINERALSTOFFWECHSEL, 2008, 15 (04): : 217 - +
  • [6] Comparative Effectiveness of Nonbiologic versus Biologic Disease-modifying Antirheumatic Drugs for Rheumatoid Arthritis
    DeWitt, Esi Morgan
    Li, Yanhong
    Curtis, Jeffrey R.
    Glick, Henry A.
    Greenberg, Jeffrey D.
    Anstrom, Kevin J.
    Kremer, Joel M.
    Reed, George
    Schulman, Kevin A.
    Reed, Shelby D.
    JOURNAL OF RHEUMATOLOGY, 2013, 40 (02) : 127 - 136
  • [7] BONE STATUS OF RHEUMATOID ARTHRITIS PATIENTS TREATED WITH BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
    Miladi, S.
    Ben Ayed, H.
    Makhlouf, Y.
    Boussaa, H.
    Ouenniche, K.
    Souabni, L.
    Kassab, S.
    Chekili, S.
    Ben Abdelghani, K.
    Fazaa, A.
    Laatar, A.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 35 : S447 - S447
  • [8] Anaphylactic Reaction to Anakinra in a Rheumatoid Arthritis Patient Intolerant to Multiple Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs
    Desai, Ditina
    Goldbach-Mansky, Raphaela
    Milner, Joshua D.
    Rabin, Ronald L.
    Hull, Keith
    Pucino, Frank
    Colburn, Nona
    ANNALS OF PHARMACOTHERAPY, 2009, 43 (05) : 967 - 972
  • [9] American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
    Saag, Kenneth G.
    Teng, Gim Gee
    Patkar, Nivedita M.
    Anuntiyo, Jeremy
    Finney, Catherine
    Curtis, Jeffrey R.
    Paulus, Harold E.
    Mudano, Amy
    Pisu, Maria
    Elkins-Melton, Mary
    Outman, Ryan
    Allison, Jeroan J.
    Almazor, Maria Suarez
    Bridges, S. Louis, Jr.
    Chatham, W. Winn
    Hochberg, Marc
    Maclean, Catherine
    Mikuls, Ted
    Moreland, Larry W.
    O'Dell, James
    Turkiewicz, Anthony M.
    Furst, Daniel E.
    ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2008, 59 (06): : 762 - 784
  • [10] Evaluation of Response Criteria in Rheumatoid Arthritis Treated With Biologic Disease-Modifying Antirheumatic Drugs
    Inoue, Mariko
    Kanda, Hiroko
    Tateishi, Shoko
    Fujio, Keishi
    ARTHRITIS CARE & RESEARCH, 2020, 72 (07) : 942 - 949